Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
Noema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.
Antiverse Ltd.s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development.
British anti-aging therapeutics developer 5 Alarm Bio Ltd has raised £500K in a seed financing for testing its lead compound FAB001 for healing chronic wounds.
French Abivax SA has raised €130m capital led by TCGX to accelerate Phase III testing of its ulcerative colitis candidate obefazimod extend its cashflow.
Myoglobin producer Paleo NV has closed a € 12 m Series A round led by DSM Venturing and Planet A Ventures.
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
With Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.